Every 8-K that Medpace Holdings, Inc. (MEDP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MEDP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MEDP filings page.
Medpace Holdings, Inc. reported second quarter 2026 revenue of $707.3 million, up 17.2% from $603.3 million a year earlier, with backlog of $3,014.2 million, up 4.9%. Net new business awards reached $795.7 million, 28.2% above the prior-year period and producing a net book-to-bill ratio of 1.13x. GAAP net income was $121.4 million, or $4.25 per diluted share, versus $90.3 million, or $3.10 per diluted share, and net income margin improved to 17.2% from 15.0%. EBITDA rose to $153.4 million, representing a 21.7% margin.
For the six months ended June 30, 2026, revenue was $1,413.9 million, up 21.7% year over year, with GAAP net income of $245.2 million and EBITDA of $302.8 million. Cash and cash equivalents were $502.7 million, and operating activities generated $162.0 million of cash in the quarter. Medpace repurchased 705,616 shares for $294.7 million, leaving $527.0 million available under its share repurchase program. For full year 2026, the company forecasts revenue of $2.805–$2.885 billion, GAAP net income of $494.0–$514.0 million, EBITDA of $618.0–$642.0 million, and diluted EPS of $17.25–$17.95.
Medpace Holdings, Inc. has appointed Brad W. Hansman, age 43, as Executive Vice President, Operations effective June 1, 2026. In this role he will perform the functions of principal operating officer alongside existing Executive Vice President, Operations, Susan E. Burwig.
Hansman has been with Medpace since 2011, progressing through finance and key operational leadership roles overseeing study start-up, logistics, regulatory affairs, and medical writing. Earlier in his career he worked at Joseph Decosimo & Company and Macy’s and holds a BBA in Accounting and is a Certified Public Accountant (inactive).
In connection with the new role, Hansman will receive an annual base salary of $492,250, be eligible for the company’s short-term cash bonus plan based on a percentage of salary, and may receive awards under the long-term equity incentive plan at the Compensation Committee’s discretion. He has entered into Medpace’s standard indemnification agreement for executive officers.
Medpace Holdings, Inc. reported results of its 2026 annual stockholder meeting and related governance changes. Stockholders approved amendments to the Restated Certificate of Incorporation to remove supermajority voting requirements and to remove the prior limitation on stockholders calling special meetings, effective upon Delaware filing on May 18, 2026. The Board also amended the bylaws so one or more stockholders owning at least 25% of the Company’s voting power, and having held it continuously for one year, may request a special meeting, subject to notice and information requirements. Stockholders elected all director nominees, ratified Deloitte & Touche LLP as auditor for the year ending December 31, 2026, approved the advisory vote on executive compensation, and supported holding this advisory vote every year.
Medpace Holdings, Inc. reported strong first quarter 2026 results with revenue of $706.6 million, up 26.5% from $558.6 million a year earlier. GAAP net income was $123.9 million, or $4.28 per diluted share, compared with $114.6 million, or $3.67 per diluted share, as net income margin moved from 20.5% to 17.5%.
EBITDA increased 25.9% to $149.4 million with a 21.1% margin, while backlog rose 2.9% to $2,929.2 million and net new business awards were $618.4 million, yielding a 0.88x net book-to-bill ratio. Cash and cash equivalents reached $652.7 million. For full year 2026, Medpace forecasts revenue of $2.755–$2.855 billion, GAAP net income of $487.0–$511.0 million, EBITDA of $605.0–$635.0 million, and diluted EPS of $16.68–$17.50. The company also announced that President Jesse Geiger will retire effective May 31, 2026, with CEO August Troendle reassuming the President role until a successor is appointed.
Medpace Holdings reported strong growth for the fourth quarter and full year 2025 and issued upbeat 2026 guidance. Fourth quarter 2025 revenue rose 32.0% to $708.5 million, with net income of $135.1 million, or $4.67 per diluted share, and a net book-to-bill ratio of 1.04x. Backlog reached $3,027.2 million at year-end.
For full year 2025, revenue grew 20.0% to $2,530.2 million and GAAP net income increased to $451.1 million, or $15.28 per diluted share, though net income margin eased to 17.8%. EBITDA was $557.7 million with a 22.0% margin.
Medpace generated $713.2 million in operating cash flow in 2025 and repurchased 2,961,924 shares for $912.9 million, ending the year with $497.0 million in cash and $821.7 million remaining under its repurchase authorization. For 2026, the company projects revenue of $2.755–$2.855 billion, GAAP net income of $487.0–$511.0 million, EBITDA of $605.0–$635.0 million, and diluted EPS of $16.68–$17.50.
Medpace Holdings, Inc. furnished an 8-K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference.
The company states the information in Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed "filed" under the Exchange Act. MEDP’s common stock trades on the NASDAQ Global Select Market.